Soligenix, Inc. (NASDAQ:SNGX) Short Interest Down 80.9% in March

Soligenix, Inc. (NASDAQ:SNGX) saw a significant decrease in short interest in March. As of March 15th, there was short interest totalling 67,700 shares, a decrease of 80.9% from the February 29th total of 354,500 shares. Approximately 0.7% of the company’s stock are short sold. Based on an average daily volume of 1,180,000 shares, the short-interest ratio is currently 0.1 days.

Soligenix Price Performance

Shares of Soligenix stock traded down $0.01 during midday trading on Thursday, hitting $0.59. The company’s stock had a trading volume of 55,832 shares, compared to its average volume of 1,232,320. The stock has a 50-day simple moving average of $0.68 and a 200-day simple moving average of $0.61. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.52 and a current ratio of 1.55. Soligenix has a 1-year low of $0.38 and a 1-year high of $4.20.

Soligenix (NASDAQ:SNGX) last issued its quarterly earnings results on Friday, March 15th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.03. The firm had revenue of $0.25 million during the quarter, compared to the consensus estimate of $0.20 million. Soligenix had a negative net margin of 731.94% and a negative return on equity of 251.07%. As a group, equities research analysts predict that Soligenix will post 0.81 EPS for the current year.

Institutional Investors Weigh In On Soligenix

Several large investors have recently modified their holdings of the stock. Renaissance Technologies LLC grew its holdings in Soligenix by 45.5% during the 2nd quarter. Renaissance Technologies LLC now owns 52,800 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 16,500 shares during the last quarter. Vanguard Group Inc. lifted its position in shares of Soligenix by 90.0% in the fourth quarter. Vanguard Group Inc. now owns 50,865 shares of the biopharmaceutical company’s stock valued at $39,000 after buying an additional 24,100 shares during the last quarter. State Street Corp boosted its holdings in shares of Soligenix by 54.0% during the second quarter. State Street Corp now owns 72,964 shares of the biopharmaceutical company’s stock worth $44,000 after acquiring an additional 25,594 shares during the period. Finally, Anson Funds Management LP acquired a new stake in shares of Soligenix in the second quarter valued at approximately $362,000. 3.60% of the stock is currently owned by institutional investors.

Soligenix Company Profile

Soligenix, Inc, a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer.